AMCP CEO Discusses Adherence, Out-of-Pocket Costs, and Concerns over the Inflation Reduction Act

In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence.

While cost-sharing can be expressed as a well-intended benefit design, studies show it can negatively affect long-term adherence, Cantrell shared. AMCP supports efforts to reduce out-of-pocket costs, however when it comes to premiums and long-term consequences, there could be consequences.

Related: AMCP’s Susan Cantrell Suggests Collaborative Solutions to Address High Drug Prices and Healthcare Disparities in Underserved Communities

She also highlighted the Inflation Reduction Act (IRA), expressing concerns about potential unintended consequences, such as manufacturers adjusting launch prices.

AMCP historically opposes government intervention in pricing, as it’s important to monitor any cost-shifting changes. Cantrell added AMCP actively works with others, sharing thoughts and helpful materials about how policies are put into action.